Ferronova announces preliminary results of MAGMAP, a 62-patient gastric and oesophageal cancer trial investigating lymph node mapping
- Written by: Business Daily Media
- Published in PR Newswire
The findings were presented today by principal investigator Dr Markus Trochsler at the 22nd ISDE World Congress for Esophageal Diseases held in Kyoto, Japan.
The lead study site was Royal Adelaide Hospital with participating hospitals and research organisations including the Peter MacCallum Cancer Centre, Austin Hospital, the Olivia Newton John Cancer Research Institute, Flinders Medical Centre, The Queen Elizabeth Hospital, and the South Australian Health and Medical Research Institute Clinical & Research Imaging Centre.
Key findings
- FerroTrace® was administered to 62 patients with no toxicity related adverse events.
- In 24 patients considered potentially suitable for a de-escalated surgical approach, 18 had pre-operative chemotherapy (75%). Sentinel nodes were identified in 23 of these patients (identification rate of 96%), no false negatives were observed among the seven node-positive patients evaluated (FNR=0%), and the patient level negative predictive value of sentinel node pathology was 100% (n=16).
- In 26 patients with gastric-oesophageal junction or distal oesophageal cancers 10 were node positive. The FerroTrace sentinel node drainage direction corresponded to the positive node direction in all 10 patients. Of 19 patients with Siewert Type I or II cancers, seven had drainage confirmed to the gastric lymphatic basin, highlighting the potential for lymphatic mapping to inform less extensive surgery in selected patients.
- Overall, 68% of patients had at least one identified sentinel lymph node outside the tissue removed using standard of care surgery.
Dr Trochsler said using radioisotopes and dyes for identification of lymph nodes draining a primary tumour is already a standard of care in breast cancer and melanoma and is highly effective. However, efforts to translate this technology to gastric and oesophageal cancer patients, who typically undergo chemotherapy or radiotherapy before surgery, have been unsuccessful to date.
"To our knowledge, this study was the first where a marker was injected prior to pre-surgical chemotherapy or radiotherapy and shown to persist and be detectable at the time of surgery. The preliminary results are extremely promising.
"The absence of false-negatives and the high negative predictive value observed in this preliminary cohort of patients with earlier-stage disease are encouraging and suggest the potential to minimise surgery in selected patients. Future research will build on these findings by investigating a larger patient cohort. We hope this ongoing work will identify new opportunities to individually tailor treatment approaches."
Mr Geoff Parnell, GI cancer survivor, patient advocate, and Chair of GI Cancer Trials (Australia), said new developments to improve the patient experience were vital.
"Those with lived experience know the journey of a patient with oesophageal or stomach cancer isn't pretty," Mr Parnell said.
"I was lucky to have found the cancer very early and purely by accident, but the surgery and long recovery was tough.
"This new study sponsored by Ferronova will help us investigate approaches that improve quality of life for patients without compromising long-term survival, while ideally also improving overall outcomes. This is particularly important because the outlook for patients with gastric and oesophageal cancers remains relatively poor."
Ferronova's CEO Mr Stewart Bartlett and the clinical team will be at the Kyoto conference until Friday 18th September at booth number 7.
ENDS
BACKGROUND NOTES
Dr Trochsler MD FMH MMIS FRACS leads the Upper Gastrointestinal and Hepatobiliary Surgery Unit at The Queen Elizabeth Hospital in Adelaide, Australia, is a senior consultant at the Royal Adelaide Hospital, and a senior lecturer in surgery at Adelaide University. He has authored more than 100 peer-reviewed research publications and contributes to numerous multidiscipline projects in cancer and clinical science.
ABOUT FERRONOVA
Ferronova is an Australian medical technology company headquartered in Adelaide, South Australia. Its mission is to improve treatment options in early stage, complex cancers and increase survival rates with its unique surgical oncology marker system. Shareholders include Renew Pharmaceuticals Limited (subsidiary of UltraGreen.ai), Uniseed/UniSuper, the South Australian Venture Capital Fund (SAVCF), Artesian Venture Partners, the University of South Australia, Powerhouse Ventures, the Victoria University of Wellington in New Zealand, the University of Sydney, PAN Ventures, STOIC Venture Capital, and Perennial Partners Future of Healthcare Fund. Grant assistance has been provided by the SA Government since 2016 and through the Federal Government's BioMedTech Horizons Program, operated by MTPConnect and Australian Government CRC-P program. For more information go to: www.ferronova.com.au
PHOTOS AND VIDEO FOOTAGE
Available for download here, please acknowledge source: Photos and Videos
Media Contact:
Bartlett Stewart
stewart.bartlett@ferronova.com.au
0403951272
